跳至主要内容
临床试验/CTRI/2018/05/013588
CTRI/2018/05/013588已完成不适用

A comparitive study of efficacy of preoperative administration of single high dose intravenous tranexamic acid versus multiple boluses of intravenous tranexamic acid in primary total knee arthroplasty

SUNSHINE HOSPITALS1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2018年5月5日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
1
主要终点
-Total blood loss

研究概览

简要总结

This is a randomised parallel group placebo controlled, single centre study to compare the efficacy of intravenous tranexamic acid administration of a single large dose or multiple timed doses in total knee replacement. This study is conducted in sunshine hospitals, Secunderabad, Telangana.

The primary outcomes are blood loss, change in hematocrit levels on 2nd postoperative day.

The secondary outcomes are transfusion rates, deep venous thrombosis, pulmonary embolisation rates.

References:

  1. Seol YJ, Seon JK, Lee SH, et al. Effect of tranexamic acid on blood loss and  blood

transfusion reduction after total knee arthroplasty. Knee Surg Relat Res.

2016;28:188–93. doi:10.5792/ksrr.2016.28.3.188

2.  Maniar RN, Kumar G, Singhi T, et al. Most effective regimen of tranexamic acid in

knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin

Orthop Relat Res 2012;470: 2605–12.

  1. Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma

fibrinolysis during total knee arthroplasty. Thromb Res1997;85:195–206

  1. Banerjee S, Kapadia BH, Issa K, et al. Postoperative blood loss prevention in total

knee arthroplasty. J Knee Surg 2013;26:395–400

  1. Seo JG, Moon YW, Park SH, et al. The comparative efficacies of intraarticular and IV

tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg

Sports Traumatol Arthrosc 2013;21: Soni A, Saini R, Gulati A, et al. Comparison

between intravenous and intra-articular regimens of tranexamic acid in reducing blood

loss during Total knee arthroplasty. J Arthroplasty 2014;29:1525–7

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Informed consent Those undergoing primary unilateral knee replacement.

排除标准

  • Abnormal PT/APTT/INR or coagulopathic diseases Undergoing B/L TKR / revision surgeries of any cause Past h/o thromboembolic events Treated with Aspirin or any anti-platelets within 1 week prior to the surgery TKR done for secondary OA (rheumatoid arthritis, post traumatic arthritis) History of reported allergy to tranexamic acid Pre operative hemoglobin <8gm/dl Chronic renal insufficiency.

结局指标

主要结局

-Total blood loss

时间窗: -Total blood loss | -Change in hematocrit levels on post-operative day 2

-Change in hematocrit levels on post-operative day 2

时间窗: -Total blood loss | -Change in hematocrit levels on post-operative day 2

次要结局

  • 1.Transfusion rates(2.Deep vein thrombosis)

研究者

申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验